Liver involvement in cystic fibrosis

Current Treatment Options in Gastroenterology

Volumn 9, Issue 6, 2006, Pages 484-496

  Brigman, Catherine ^b   Feranchak, Andrew ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADEK; ALPHA TOCOPHEROL; AMIODARONE; ANTACID AGENT; ANTICOAGULANT AGENT; CALCIUM; CALCIUM CARBONATE; COLESTIPOL; COLESTYRAMINE; CONTRACEPTIVE AGENT; CREON 10; CREON 20; CREON 5; DIGOXIN; DIURETIC AGENT; ENZYME; KREON; LINOLEIC ACID; LINOLENIC ACID; LIQUIE; MAGNESIUM HYDROXIDE; OCTREOTIDE; PANCRECARB; PANCRECARB MS 16; PANCRECARB MS 4; PANCRECARB MS 8; PANCRELIPASE; POLY VI SOL; PROPRANOLOL; RETINOL; RIFAMPICIN; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TOCOFERSOLAN; ULTRASE MT12; ULTRASE MT18; ULTRASE MT20; UNCLASSIFIED DRUG; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VASOPRESSIN; VIOKASE 16; VIOKASE 8; VIOKASE POWDER; VITAMAX; VITAMIN D; VITAMIN K GROUP; ZINC;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; AGRANULOCYTOSIS; ALPHA TOCOPHEROL DEFICIENCY; ANOREXIA; ASCITES; ASTHMA; BIOCHEMISTRY; CONFUSION; CONSTIPATION; CYSTIC FIBROSIS; DIARRHEA; DIET THERAPY; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG POTENTIATION; ECHOGRAPHY; ENDOSCOPIC SCLEROTHERAPY; ESOPHAGUS VARICES; FLATULENCE; FLU LIKE SYNDROME; GASTRITIS; GYNECOMASTIA; HEARTBURN; HEMOLYTIC ANEMIA; HEPATOBILIARY DISEASE; HUMAN; HYPERKALEMIA; LETHARGY; LIFESTYLE; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; LIVER FUNCTION; LIVER INJURY; LIVER TOXICITY; LIVER TRANSPLANTATION; METABOLIC ACIDOSIS; MUCOSA INFLAMMATION; NAUSEA; NUTRITION; PATIENT MONITORING; PHYSICAL EXAMINATION; PORTAL HYPERTENSION; PORTOSYSTEMIC ANASTOMOSIS; POSTOPERATIVE COMPLICATION; PREDICTION; PRURITUS; RETINOL DEFICIENCY; REVIEW; SHUNTING; SOMNOLENCE; STEATORRHEA; STEATOSIS; STOMACH HEMORRHAGE; THROMBOCYTOPENIA; URTICARIA; VITAMIN D DEFICIENCY; VITAMIN K DEFICIENCY; VOMITING;

EID: 33751316323     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-006-0005-8     Document Type: Review

References (62)

1. Dodge JA, Morison S, Lewis PA, et al.: Incidence, population, and survival of cystic fibrosis in the UK, 1968-95. UK Cystic Fibrosis Survey Management Committee. Arch Dis Child 1997, 77:493-496.
2. Kosorok MR, Wei WH, Farrell PM: The incidence of cystic fibrosis. Stat Med 1996, 15:449-462.
3. Riordan JR, Rommens JM, Kerem B, et al.: Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989, 245:1066-1073.
4. Gaskin, Kj, Waters DL, de Silva M, et al.: Liver disease and bile duct stenosis in cystic fibrosis. Lancet 1990, 335:1098.
5. Linblad A, Glaumann H, Strandvik B: Natural history of liver disease in cystic fibrosis. Hepatology 1999, 30:1151-1158.
6. Colombo C, Battezzati PM, Crosignani A, el al.: Liver disease in cystic fibrosis: a prospective study on incidence, risk factors, and outcome. Hepatology 2002, 36:1374-1382.
7. Cohn J, Strong T, Picciotto M, et al.: Localization of the cystic fibrosis transmembrane conductance regulator in human bile duct epithelial cells. Gastroenterology 1993, 105:1857-1864.
8. Sharma R, Florea VG, Bolger AP, et al.: Wasting as an independent predictor of mortality in patients with cystic fibrosis. Thorax 2001, 56:746-750.
9. Littlewood JM: An overview of the management of cystic fibrosis. J R Soc Med 1986, 79(Suppl 12):55-63.
10. Ramsey BW, Farrell PM, Pencharz PB, et al.: Nutritional assessment and management in cystic fibrosis: a consensus report. Am J Clin Nutr 1992, 55:108-116.
11. Waters DL, Dorney SE Gruca MA, et al.: Hepatobiliary disease in cystic fibrosis patients with pancreatic sufficiency. Hepatology 1995, 21:963-969.
12. Borowitz D, Baker SS, Duffy L, et al.: Use of fecal elastase-1 to classify pancreatic status in patients with cystic fibrosis. J Pediatr 2004, 145:322-326.
13. Schibli S, Durie P, Tullis E: Proper use of pancreatic enzymes. Curr Opin Pulm Med 2002, 8:542-546.
14. FitzSimmons SC, Burkhart GA, Borowitz D, et al.: High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. N Engl J Med 1997, 336:1283-1289.
15. Borowitz DS, Grand RJ, Durie PR: Use of pancreatic enzyme supplements for patients with cystic fibrosis in the setting of fibrosing colonopathy. Consensus Committee. J Pediatr 1995, 127:681-684.
16. Feranchak A, Sontag M, Wagener J, et al.: Prospective, long-term study of fat-soluble vitamin status in children with cystic fibrosis identified by newborn screen. J Pediatr 1999, 135:601-610.
17. Feranchak A, Gralla J, King R: Comparisons of indices of vitamin A status in children with chronic liver disease. Hepatology 2005, 42:782-791.
18. Borowitz D, Baker RD, Stallings V: Consensus report on nutrition for pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 2002, 35:246-259.
19. Pencharz PB, Durie PR: Nutritional management of cystic fibrosis. Annu Reu Nutr 1993, 13:111-136.
20. Dowsett J: An overview of nutritional issues for the adult with cystic fibrosis. Nutrition 2000, 16:566-570.
21. Sanders T: Essential fatty acids. In Encyclopedia of Food Science, Food Technology and Nutrition. Edited by Macrae R, Robinson RK, Sadler MJ. San Diego: Academic Press; 1993:1653.
22. Nussbaum MS, Li S, Bower RH, et al.: Addition of lipid to total parenteral nutrition prevents hepatic steatosis in rats by lowering the portal venous insulin/glucagon ratio. JPEN J Parenter Enteral Nutr 1992, 16:106-109.
23. Gould KL, Martucci JP, Goldberg DI, et al.: Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential noninvasive marker of healing coronary endothelium [comment]. Circulation 1998, 97:2580-2583.
24. Fickert P, Zollner G, Fuchsbichler A, et al.: Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. Gastroenterology 2001, 121:170-183.
25. Rost D, Rudolph G, Kloeters-Plachky P, et al: Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis. Hepatology 2004, 40:693-698.
26. Beuers U: Drug insight: mechanism and sites of action of ursodexycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol 2006, 3:318-328.
27. Van Nieuwkerk CM, Elferink RP, Groen AK, et al.: Effects of Ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glyco-protein gene. Gastroenterology 1996, 111:165-171.
28. Azzaroli F, Mehal W, Soroka CJ, et al.: Ursodeoxycholic acid diminishes Fas-ligand-induced apoptosis in mouse hepatocytes. Hepatology 2002, 36:49-54.
29. Tanaka H, Makino Y, Miura T, et al.: Ligand-independent activation of the glucocorticoid receptor by ursodeoxycholic acid. Repression of IFN-gamma-induced MHC class II gene expression via a glucocorticoid receptor-dependent pathway. J Immunol 1996, 156:1601-1608.
30. Colombo C, Battezzati PM, Podda M, et al.: Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double blind multicenter trial. Hepatology 1996, 23:1484-1490.
31. Colombo C, Crosignani A, Assaisso M, et al.: Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response study. Hepatology 1992, 16:924-929.
32. Colombo C, Castellani MR, Balistreri WF, et al.: Scintigraphic documentation of an improvement in hepatoboliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease. Hepatology 1992, 15:677-684.
33. Lindblad A, Glaumann H, Strandvik B: A two year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease. Hepatology 1998, 27:166-174.
34. Sokol R, Durie P: Recommendations for management of liver and biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group. JPGN 1999, 28(Suppl 1):SI-SI3.
35. Garden JM, Ostrow JD, Roenigk HH, Jr: Pruritis in hepatic cholestasis - pathogenesis and treatment. Arch Dermatol 1985, 121:1415-1420.
36. Jones EA, Bergasa NV The pruritis of cholestasis: from bile acids to opiate antagonists. Hepatology 1990, 11:884-887.
37. Yerashalmi B, Sokol RJ, Narkewicz MR: Use of rifampin for severe pruritis in children with chronic cholestasis. J Pediatr Gastroenterol Nutr 1999, 29:442-447.
38. Ozsoylu S, Kocak N, Yuca A: Propranolol therapy for portal hypertension in children. J Pediatr 1985, 106:317-321.
39. Sanyal Al, Shiffman ML: Pharmacological treatment of portal hypertension. In Current Clinical Topics in Gastrointestinal Pharmacology. Edited by Lewis JH, Dubois A. London: Blackwell Scientific; 1997:242-275.
40. Bessan I, Ingraud P, Pearson B, et al.: Sclerotherapy with or without octreotide for acute variceal bleeding. N Engl J Med 1995, 333:555-560.
41. Gaudy H, Rosman A, Korssen M: Prevention of stricture formation after endoscopic sclerotherapy of esophageal varices. Gastrointest Endosc 1989, 35:377-380.
42. Laine L, Cook D: Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding. A meta-analysis. Ann Intern Med 1995, 123:280-287.
43. Fox VL, Carr-Locke DL, Connors PJ, et al.: Endoscopic ligation of esophageal varices in children. J Pediatr Gastroenterol Nutr 1995, 20:202-208.
44. Howard ER, Stringer MD, Mowat AP: Assessment of injection sclerotherapy in the management of 152 children with esophageal varices. Br J Surg 1988, 75:404-408.
45. Stringer MD, McClean P: Treatment of oesophageal varices. Arch Dis Child 1997, 77:476-477.
46. Boyer TD, Vargus EV: Transjugular intrahepatic porto-systemic shunt. In Schiff's Diseases of the Liver, edn 9. Edited by Schiff ER, Sorrell MF, Maddrey WC. Philadelphia: Lippincott Williams &Williams; 2003:369-382.
47. Rossle M, Siegerstetter V, Huber M, Ochs A: The first decade of the transjugular intrahepatic portosystemic shunt (TIPS): state of the art. Liver 1998, 18:73-89.
48. Sanyal AJ: TIPS: the new kid on the block. Hepatology 1994, 20:1092-1095.
49. Luketic VA, Sanyal Al: Esophageal varices. II TIPS (transjugular intrahepatic portosystemic shunt) and surgical therapy. Gastroenterol Clin North Am 2000, 29:387-421.
50. Pozler O, Krajina A, Vanicek H: Transjugular intrahepatic portosystemic shunt in five children with cystic fibrosis: long-term results. Hepatogastroenterology 2003, 50:1111-1114.
51. Fleet M, Stanley Al, Forrest EIL et al.: Transjugular intrahepatic portosystemic stent shunt placement with cystic fibrosis complicated by portal hypertension. Clin Radiol 2000, 55:236-237.
52. Sergent G, Gottrand F, Delemazure O, et al.: Transjugular intrahepatic portosystemic shunt in an infant. Pediatr Radiol 1997, 27:588-590.
53. Kerns SR, Hawkins IF, Jr: Transjugular intrahepatic portosystemic shunt in a child with cystic fibrosis. AJR Am J Roentgenol 1992, 159:1277-1278.
54. Shneider BL: Portal hypertension. In Liver Disease in Children, edn 2. Edited by Suchy F, Sokol R, Ballisteri W. Philadelphia: Lippincott Williams & Wilkins; 2001:144.
55. Valayer J, Hay JM, Gauthier E et al.: Shunt surgery for treatment of portal hypertension in children. World J Surg 1985, 9:258-268.
56. Colombo C: Management of CF complications: liver disease. Paper presented at 2005 Cystic Fibrosis Conference. Baltimore, MD; October 20-23, 2005.
57. Colombo Q Costantini D, Rocchi A, et al.: Effects of liver transplantation on the nutritional status of patients with cystic fibrosis. Transpl Int 2005, 18:246-255.
58. Fridell JA, Bond GJ, Mazariegos GV: Liver transplantation in children with cystic fibrosis: a long-term longitudinal review of a single center's experience. J Pediatr Surg 2003, 38:1152-1156.
59. Couetil JP, Soubrane O, Houssin DP: Combined heart-lung-liver, double lung-liver, and isolated liver transplantation for cystic fibrosis in children. Transpl Int 1997, 10:33-39.
60. Molmenti EP, Squires RH, Nagata D: Liver transplantation for cliolestasis associated with cystic fibrosis in the pediatric population. Pediatr Transplant 2003, 7:93-97.
61. Ling SC, Wilkinson JD, Hollman AS, et al.: The evolution of liver disease in cystic fibrosis. Arch Dis Child 1999, 81:129-132.
62. Goodin B: Nutrition issues in cystic fibrosis. Pract Gastroenterol 2005, 27:76-94.